CHARACTERISTICS OF PROLIFERATION AND INTERCELLULAR ADHESION IN PRE-CANCEROUS AND MALIGNANT EPITHELIAL SKIN TUMORS

Cover Page


Cite item

Abstract

Background: Differential diagnostics between actinic keratosis which is one of pre-cancerous skin diseases, and intra-epidermal squamous cell skin cancer (or Bowen's disease) could be difficult in some cases even with morphological examination. The study on molecular characteristics of pre-cancerous skin disorders would allow for more accurate diagnostics and assessment of prognosis. Aim: To study proliferative activity of keratinocytes and E-cadherin expression on cell membranes in actinic keratosis and in Bowen's disease, with identification of differential diagnostic criteria. Materials and methods: We performed an immunohistochemistry study with anti-Ki-67 and anti-Е-cadherin monoclonal antibodies in skin bioptates of 23 patients with actinic keratosis and 10 patients with Bowen's disease. Results: The mean proliferation index in actinic keratosis without the bowen-like loci was 30.9 ± 11.4% (range, from 11.5 to 48.4%), and in actinic keratosis with the bowen-like loci, 40.3 ± 8.6% (range, from 31 to 57.6%). In both groups, E-cadherin expression in all cases (100%) was located in cell membranes. The mean proliferation index in Bowen's disease was 44.7 ± 8.2% (range, from 33.3 to 60%). In 48.2% of Bowen cells, abnormal type of E-cadherin expression (reduced membranous, membranous and cytoplasmatic and cytoplasmatic only). Conclusion: Actinic keratosis and Bowen's disease represent different stages of one and the same malignant process that have different proliferative cell activity and E-cadherin expression, which could be used as differential diagnostic markers.

About the authors

A. N. Khlebnikova

I.M. Sechenov First Moscow State Medical University; 8/2 Trubetskaya ul., Moscow, 119991, Russian Federation

Author for correspondence.
Email: alb9696@yandex.ru
MD, PhD, Professor, Chair of Skin and Venereal Diseases, Institute for Professional Education Russian Federation

L. E. Gurevich

Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation

Email: alb9696@yandex.ru
MD, PhD, Leading Research Fellow, Department of Pathological Anatomy Russian Federation

E. V. Selezneva

I.M. Sechenov First Moscow State Medical University; 8/2 Trubetskaya ul., Moscow, 119991, Russian Federation

Email: alb9696@yandex.ru
MD, PhD, Assistant, Chair of Skin and Venereal Diseases, Institute for Professional Education Russian Federation

K. V. Obydenova

Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation

Email: alb9696@yandex.ru
MD, PhD Student, Chair of Dermatovenereology and Dermato-Oncology, Postgraduate Training Faculty Russian Federation

T. G. Sedova

Perm State Medical Academy named after academician E.A.Vagner; 26 Petropavlovskaya ul., Perm, 614990, Russian Federation

Email: alb9696@yandex.ru

MD, PhD, Associate Professor, Chair of Dermatology and Venereology

Russian Federation

Zh. S. Kuntsevich

Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation

Email: alb9696@yandex.ru
MD, PhD, Associate Professor, Chair of Dermatovenereology and Dermato-Oncology, Postgraduate Training Faculty Russian Federation

References

  1. Marks R. The epidemiology of non-melanoma skin cancer: who, why and what can we do about it. J Dermatol. 1995;22(11):853–7.
  2. Housman TS, Feldman SR, Williford PM, Fleischer AB Jr, Goldman ND, Acostamadie-do JM, Chen GJ. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol. 2003;48(3):425–9.
  3. Marks R, Foley P, Goodman G, Hage BH, Sel-wood TS. Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol. 1986;115(6):649–55.
  4. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1988;1(8589):795–7.
  5. Dodson JM, DeSpain J, Hewett JE, Clark DP. Malignant potential of actinic keratoses and the controversy over treatment. A patient-oriented perspective. Arch Dermatol. 1991;127(7):1029–31.
  6. McCabe M, Nowak M, Maguire D, Robert-son P. Immunosuppression by human skin cancers. Aust J Exp Biol Med Sci. 1984;62 (Pt 5):539–45.
  7. Молочков ВА. Плоскоклеточный рак кожи. Вестник дерматологии и венерологии. 1997;(6):44–8.
  8. Cockerell CJ, Wharton JR. New histopathological classification of actinic keratosis (incipient intraepidermal squamous cell carcinoma). J Drugs Dermatol. 2005;4(4):462–7.
  9. Elder DE, Elenitsas R, Johnson BL Jr, Murphy GF, eds. Lever's Histopathology of the Skin. 9th Edition. Philadelphia: Lippincott Williams & Wilkins; 2005. 645 p.
  10. Bagazgoitia L, Cuevas J, Juarranz A. Expression of p53 and p16 in actinic keratosis, bowenoid actinic keratosis and Bowen's disease. J Eur Acad Dermatol Venereol. 2010;24(2):228–30. doi: 10.1111/j.1468-3083.2009.03337.x.
  11. Hashimoto K, Mehregan AH. Tumors of the epidermis. Stoneham: Butterworth; 1990.
  12. Ishida H, Kumakiri M, Ueda K, Lao LM, Yanagihara M, Asamoto K, Imamura Y, Noriki S, Fukuda M. Comparative histochemical study of Bowen's disease and actinic keratosis: preserved normal basal cells in Bowen's disease. Eur J Histochem. 2001;45(2):177–90.
  13. Carpenter PM, Linden KG, McLaren CE, Li KT, Arain S, Barr RJ, Hite P, Sun JD, Meyskens FL Jr. Nuclear morphometry and molecular bio-markers of actinic keratosis, sun-damaged, and nonexposed skin. Cancer Epidemiol Bio-markers Prev. 2004;13(12):1996–2002.
  14. Tilli CM, Ramaekers FC, Broers JL, Hutchison CJ, Neumann HA. Lamin expression in normal human skin, actinic keratosis, squamous cell carcinoma and basal cell carcinoma. Br J Dermatol. 2003;148(1):102–9.
  15. Talghini S, Halimi M, Baybordi H. Expression of p 27, Ki 67, p 53 in squamous cell carcinoma, actinic keratosis and Bowen disease. Pakistan Journal of Biological Sciences. 2009;12(12):929–33. doi: 10.3923/ pjbs.2009.929.933.
  16. Lyakhovitsky A, Barzilai A, Fogel M, Trau H, Huszar M. Expression of e-cadherin and beta-catenin in cutaneous squamous cell carcinoma and its precursors. Am J Dermatopathol. 2004;26(5):372–8.
  17. Papadavid E, Pignatelli M, Zakynthinos S, Krausz T, Chu AC. Abnormal immunoreactivity of the E-cadherin/catenin (alpha-, beta-, and gamma-) complex in premalignant and malignant non-melanocytic skin tumours. J Pathol. 2002;196(2):154–62.
  18. Fuller LC, Allen MH, Montesu M, Barker JN, Macdonald DM. Expression of E-cadherin in human epidermal non-melanoma cutaneous tumours. Br J Dermatol. 1996;134(1):28–32.

Copyright (c) 2016 Khlebnikova A.N., Gurevich L.E., Selezneva E.V., Obydenova K.V., Sedova T.G., Kuntsevich Z.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies